Home Clinical Trials Update

Clinical Trials Update

Enfortumab Vedotin + Pembrolizumab to be Evaluated in Phase III Registration Trial in...

Enfortumab vedotin (also known as AGS-22ME; Seattle Genetics/Astellas), an antibody-drug conjugate (ADC), will be evaluated in a phase III...

Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma

Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of...
Daiichi Sankyo, Basking Ridge, NJ. Courtesy: Daiichi Sankyo.

Daiichi Sankyo Starts First-in-Human Phase I/II Study Evaluating DS-7300

Daiichi Sankyo, in collaboration with and Sarah Cannon Research Institute, has started the first-in-human, open label, phase I/II study...

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916),...
One red Dutch tulip

Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer

Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R Classical Hodgkin Lymphoma

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large B-cell Lymphoma

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic...

Anti-CD205 Antibody-Drug Conjugate MEN1309/OBT076 Shows Substantial in vitro Antitumor Activity

Non-clinical study findings published in the journal Molecular Cancer Therapeutics describing the characterization of the anti-CD205 antibody-drug conjugate (ADC)...
Scientists at work. Courtesy 2019 Fotolia

GTB-1550 Shows Durable Complete Remission in Patients with Chemotherapy-refractory B-cell Malignancies

The investigational anti-cancer agent GTB-1550, also known as OXS-1550 or DT2219 is a novel multi-target directed therapy for the...